Biogen has appointed Tim Power as Vice President and Head of Investor Relations, effective December 9, 2024. In this role, Mr. Power will report directly to Michael McDonnell, the company’s Executive Vice President and Chief Financial Officer. I am excited…
CVS Health Corporation has disclosed the Reference Yield and Total Consideration for its previously announced cash tender offer (the “Any and All Tender Offer”) targeting its 4.100% Senior Notes due 2025 (the “Any and All Notes”). This tender offer is…
AstraZeneca announced the appointment of Iskra Reic as Executive Vice President (EVP), International, effective immediately. Reic will oversee the company’s strategy and growth across the vast International region, including markets in China, Asia, Eurasia, the Middle East & Africa, Latin…
COUR Pharmaceuticals, a biotech company based in Chicago, has entered into a significant partnership with Roche’s Genentech to develop and commercialize treatments for an undisclosed autoimmune disease. This collaboration follows just ten months after COUR closed a $105 million Series…
Revolution Medicines a clinical-stage oncology company focused on developing therapies for RAS-addicted cancers, has announced the pricing of its upsized public offering. The offering consists of 14,130,436 shares of common stock at a public offering price of $46.00 per share…
Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical-stage botanical pharmaceutical company specializing in the development of unique botanical pharmaceutical and cosmeceutical products, has announced its financial results for the fiscal year ending July 31, 2024, as…
The global Generic Injectables market, valued at $95.2 billion in 2023, is on a strong growth trajectory and is projected to reach $206.8 billion by 2030, growing at a CAGR of 11.7% from 2023 to 2030. This comprehensive report provides…
UCB, a global biopharmaceutical leader, has announced the successful completion of its sale, divestment, and licensing agreement for its mature neurology and allergy portfolio in China. The transaction, valued at $680 million, transfers ownership of key products, including Keppra®, Vimpat®,…
The global market for head and neck cancer therapeutics is estimated to reach $1.7 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 9.4% from 2024 to 2030. By 2030, the market is…
Enanta Pharmaceuticals Delivers Key Updates on Virology and Immunology Programs While Reporting Fiscal Year 2024 Results Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company specializing in small molecule drugs for virology and immunology, announced its financial results for the…
ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on rebalancing the inflammatory response to treat rare and acute inflammatory diseases, has announced the appointment of Dr. Lewis T. “Rusty” Williams, M.D., Ph.D., as Chairman of…
Omeros Corporation (Nasdaq: OMER) has shared an update on its ongoing efforts to resubmit the biologics license application (BLA) for narsoplimab, its first-in-class antibody targeting MASP-2, a key enzyme in the lectin pathway of complement activation. Narsoplimab is being developed…